Scandinavian ChemoTech AB Series B (CMOTEC-B) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.550x

Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has a cash flow conversion efficiency ratio of -0.550x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.41 Million ≈ $-366.54K USD) by net assets (Skr6.19 Million ≈ $666.47K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Scandinavian ChemoTech AB Series B - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Scandinavian ChemoTech AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CMOTEC-B current and long-term liabilities for a breakdown of total debt and financial obligations.

Scandinavian ChemoTech AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Radiant Utama Interinsco Tbk JK:RUIS	-0.070x
Ostin Technology Group Co Ltd NASDAQ:OST	-0.096x
Intelicanna Ltd TA:INTL	-0.023x
Intrasense PA:ALINS	0.452x
Globe Kita Terang Tbk PT JK:GLOB	-0.003x
Memphasys Ltd AU:MEM	-0.306x
AUX Resources Corporation V:AUX	-0.314x
Burford Capital Limited LSE:BUR	0.048x

Annual Cash Flow Conversion Efficiency for Scandinavian ChemoTech AB Series B (2014–2024)

The table below shows the annual cash flow conversion efficiency of Scandinavian ChemoTech AB Series B from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see CMOTEC-B market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr5.98 Million ≈ $643.54K	Skr-13.14 Million ≈ $-1.41 Million	-2.198x	-33.04%
2023-12-31	Skr11.03 Million ≈ $1.19 Million	Skr-18.23 Million ≈ $-1.96 Million	-1.652x	-17.77%
2022-12-31	Skr13.99 Million ≈ $1.51 Million	Skr-19.63 Million ≈ $-2.11 Million	-1.403x	-74.92%
2021-12-31	Skr23.92 Million ≈ $2.57 Million	Skr-19.18 Million ≈ $-2.06 Million	-0.802x	+12.79%
2020-12-31	Skr9.24 Million ≈ $993.94K	Skr-8.49 Million ≈ $-914.09K	-0.920x	+20.30%
2019-12-31	Skr9.73 Million ≈ $1.05 Million	Skr-11.23 Million ≈ $-1.21 Million	-1.154x	-416.46%
2018-12-31	Skr20.50 Million ≈ $2.21 Million	Skr-4.58 Million ≈ $-492.77K	-0.223x	+84.65%
2017-12-31	Skr10.29 Million ≈ $1.11 Million	Skr-14.97 Million ≈ $-1.61 Million	-1.456x	-182.40%
2016-12-31	Skr14.58 Million ≈ $1.57 Million	Skr-7.52 Million ≈ $-808.93K	-0.515x	+5.74%
2015-12-31	Skr868.64K ≈ $93.48K	Skr-474.99K ≈ $-51.12K	-0.547x	+38.15%
2014-12-31	Skr46.27K ≈ $4.98K	Skr-40.91K ≈ $-4.40K	-0.884x	--

About Scandinavian ChemoTech AB Series B

ST:CMOTEC-B Sweden Biotechnology

Market Cap

$10.09 Million

Skr93.78 Million SEK

Market Cap Rank

#26849 Global

#583 in Sweden

Share Price

Skr3.94

Change (1 day)

-1.25%

52-Week Range

Skr1.52 - Skr7.30

All Time High

Skr51358.02